Bernd Meibohm, PhD, FCP, FAAPS

Professor and Associate Dean for Research and Graduate Programs
Past President - American College of Clinical Pharmacology

MEMPHIS TN 381630000
Tel: (901) 448-1206


  • PostDoc, University of Florida, Clinical Pharmacology
  • Ph.D., Tech.Univ. Carolo-Wilhelmina, Braunschweig, Germany, Pharmaceutical Sciences
  • B.S., Tech.Univ. Carolo-Wilhelmina, Braunschweig, Germany, Pharmacy

Research Description

Dr. Meibohm’s research is focused on the investigation of the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs with special emphasis on PK/PD-correlations.

Pharmacokinetic/pharmacodynamic (PK/PD)-modeling bridges the gap between dynamic dose-concentration relationships and static concentration-effect relationships of drugs. By combining information provided by pharmacokinetics and by pharmacodynamics, it facilitates the description and prediction of the time course of drug effects that are resulting from a certain dosing regimen. The application of these PK/PD-modeling concepts has been identified as beneficial in all phases of preclinical and clinical drug development as well as in applied clinical pharmacotherapy, where it provides a more rational basis for patient-specific dosage individualization.

Thus, the ultimate goal of the research in Dr. Meibohm’s lab is to contribute to the optimization of dosing regimens for increased efficacy and reduced toxicity and to modulate pharmacotherapy according to the needs of the individual patient.


Special areas of interest are:

- Pharmacokinetics and pharmacodynamics of small molecule drugs and biologics in pediatric patients and their dependency on developmental changes.

- Pharmacokinetics and pharmacodynamics of antibiotics with specific focus on development of therapies against tuberculosis

- Application of pharmacometrics and quantitative pharmacology concepts in preclinical and clinical drug development, with specific focus on therapeutic proteins.


This includes the application of the following research techniques:

- Evaluation of the pharmacokinetic properties of investigational as well as marketed drugs or dosage forms in animal models, healthy volunteers or various patient subpopulations.

- Participation in the planning, conduct, and analysis of clinical trials.

- Development and validation of bioanalytical assays to quantify drug concentrations in biological fluids.

- Application of molecular biology research techniques for DNA, RNA and protein analysis relevant to drug response.

- Identification and validation of surrogate endpoints as measure for the pharmacologic activity of drugs.

- Computer-based mathematical modeling and simulation of the correlation between the pharmacokinetics and pharmacodynamics of drugs (PK/PD-modeling).

- Application of population approaches in pharmacokinetic and pharmacodynamic data analysis.


Dr. Meibohm’s research group is actively collaborating with researchers and clinicians at the University of Tennessee Colleges of Pharmacy and Medicine, LeBonheur Children''s Medical Center, Memphis, TN, St. Jude Children''s Research Hospital, Memphis, TN, Colorado State University, Fort Collins, CO, the University of Düsseldorf School of Pharmacy, Düsseldorf, Germany, the Institute for Applied Healthcare Sciences, Hamburg, Germany, and in the pharmaceutical industry.

Current collaborative research projects include:

Pediatric Pharmacotherapy

- Evaluation of the effect of developmental changes on the disposition of and response to investigational and clinically used drugs in pediatric patients, with specific focus on hepatic drug transporters.

- Investigation of the pharmacokinetics and pharmacodynamics of medications used in neonatal and pediatric pharmacotherapy, including population PK/PD modeling and simulation to optimize dosing strategies and trial designs.

- Evaluation of the ontogeny of drug disposition mechanisms relevant for therapeutic proteins.

Anti-infective Pharmacotherapy

- Preclinical pharmacokinetic and pharmacodynamic evaluation and optimization of novel anti-infectives against tuberculosis and other infections.

- Pharmacometric approaches to predict in vivo efficacy of novel anti-infectives. 

Drug Development

- Pharmacokinetic and pharmacodynamic characterization including PK/PD-modeling of the investigational drugs, especially biotechnologically derived drug products.

- Pharmacokinetic and pharmacodynamic evaluation of therapeutic proteins and their mechanisms of disposition and elimination. 

Training on Pharmacokinetics and Pharmacodynamics of Protein Therapeutics

Dr. Meibohm holds annually in collaboration with Dr. Johan Gabrielsson from the Swedish University of Agricultural Sciences in Uppsala, Sweden a week-long hands-on pharmacometric training course at the University of Tennessee Health Science Center in Memphis on the Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins. For details please click here.

Research Interest/Specialty

Clinical Pharmacology
Drug Development

Research keywords

Quantitative Systems Pharmacology
Population Pharmacokinetics
Population PK/PD
Trial simulation
Nonlinear mixed effects modeling
Modeling & simulation
Monoclonal antibodies
Recombinant proteins


  1. Laizure, SC, Meibohm, B, Nelson, K, Chen, F, Hu, ZY, Parker, RB. Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects. Br J Clin Pharmacol, 83 (12), 2687-2694, 2017.
  2. Midde, NM, Gong, Y, Cory, TJ, Li, J, Meibohm, B, Li, W, Kumar, S. Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies. Pharm Res, 34 (9), 1925-1933, 2017.
  3. He, H, Ma, D, Crone, LB, Butawan, M, Meibohm, B, Bloomer, RJ, Yates, CR. Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans. J Caffeine Res, 7 (3), 95-102, 2017.
  4. Ryman, JT, Meibohm, B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol, 6 (9), 576-588, 2017.
  5. Kshirsagar, N, Swaminathan, S, Jog, P, Dalwai, S, Mathur, R, Shekhar, C, Meibohm, B, Gupta, YK, Shafiq, N, Sunkara, G, Somani, VG, Kulkarni, P, Tseng, B, Mehta, D. Regulatory and Ethical Issues in Pediatric Clinical Research: Recommendations From a Panel Discussion. J Clin Pharmacol, 57 (8), 943-946, 2017.
  6. Donnenberg, VS, Mandic, M, Rhee, JC, Burns, TF, Meibohm, B, Korth-Bradley, JM. Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics. J Clin Pharmacol, 57 (8), 947-955, 2017.
  7. Sharma, A, Weber, B, Meibohm, B. Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies. Clin Drug Investig, 37 (7), 705-707, 2017.
  8. Siricilla, S, Mitachi, K, Yang, J, Eslamimehr, S, Lemieux, MR, Meibohm, B, Ji, Y, Kurosu, M. A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. J Med Chem, 60 (7), 2869-2878, 2017.
  9. Herskovitz, J, Ryman, J, Thway, T, Lee, S, Zhou, L, Chirmule, N, Meibohm, B, Jawa, V. Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure. AAPS J, 19 (2), 447-455, 2017.
  10. Liu, J, Bruhn, DF, Lee, RB, Zheng, Z, Janusic, T, Scherbakov, D, Scherman, MS, Boshoff, HI, Das, S, Rakesh, , Waidyarachchi, SL, Brewer, TA, Gracia, B, Yang, L, Bollinger, J, Robertson, GT, Meibohm, B, Lenaerts, AJ, Ainsa, J, Böttger, EC, Lee, RE. Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. ACS Infect Dis, 3 (1), 72-88, 2017.
  11. Midde, NM, Rahman, MA, Rathi, C, Li, J, Meibohm, B, Li, W, Kumar, S. Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method. PLoS One, 11 (2), e0149225, 2016.
  12. Midde, NM, Sinha, N, Lukka, PB, Meibohm, B, Kumar, S. Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells. PLoS One, 12 (2), e0172628, 2016.
  13. Mould, DR, Meibohm, B. Drug Development of Therapeutic Monoclonal Antibodies. BioDrugs, 30 (4), 275-93, 2016.
  14. Leeder, JS, Meibohm, B. Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. Drug Metab Dispos, 44 (7), 916-23, 2016.
  15. Thomson, MM, Hines, RN, Schuetz, EG, Meibohm, B. Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. Drug Metab Dispos, 44 (7), 999-1004, 2016.
  16. Rathi, C, Lee, RE, Meibohm, B. Translational PK/PD of anti-infective therapeutics. Drug Discov Today Technol, 21-22, 41-49, 2016.
  17. Gunn, GR, Sealey, DC, Jamali, F, Meibohm, B, Ghosh, S, Shankar, G. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin Exp Immunol, 184 (2), 137-46, 2016.
  18. Madhura, DB, Trivedi, A, Liu, J, Boyd, VA, Jeffries, C, Loveless, V, Lee, RE, Meibohm, B. Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis. AAPS J, 18 (3), 788-91, 2016.
  19. Barnes, RC, Krenek, KA, Meibohm, B, Mertens-Talcott, SU, Talcott, ST. Urinary metabolites from mango (Mangifera indica L. cv. Keitt) galloyl derivatives and in vitro hydrolysis of gallotannins in physiological conditions. Mol Nutr Food Res, 60 (3), 542-50, 2016.
  20. Sharma, A, Weber, B, Wein, M, Hallmann, C, Meibohm, B. Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products. Clin Pharmacol Drug Dev, 5 (1), 52-6, 2016.
  21. Gabrielsson, J, Meibohm, B, Weiner, D. Pattern Recognition in Pharmacokinetic Data Analysis. AAPS J, 18 (1), 47-63, 2016.
  22. Madhura, DB, Liu, J, Meibohm, B, Lee, RE. Phase II Metabolic Pathways of Spectinamide Antitubercular Agents: A Comparative Study of the Reactivity of 4-Substituted Pyridines to Glutathione Conjugation. Medchemcomm, 7 (1), 114-117, 2016.
  23. Brouwer, KL, Aleksunes, LM, Brandys, B, Giacoia, GP, Knipp, G, Lukacova, V, Meibohm, B, Nigam, SK, Rieder, M, de Wildt, SN, ,. Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. Clin Pharmacol Ther, 98 (3), 266-87, 2015.
  24. Presley, C, Abidi, A, Suryawanshi, S, Mustafa, S, Meibohm, B, Moore, BM. Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Pharmacol Res Perspect, 3 (4), e00159, 2015.
  25. Diao, L, Meibohm, B. Tools for predicting the PK/PD of therapeutic proteins. Expert Opin Drug Metab Toxicol, 11 (7), 1115-25, 2015.
  26. Parker, RB, Hu, ZY, Meibohm, B, Laizure, SC. Effects of alcohol on human carboxylesterase drug metabolism. Clin Pharmacokinet, 54 (6), 627-38, 2015.
  27. Bruhn, DF, Waidyarachchi, SL, Madhura, DB, Shcherbakov, D, Zheng, Z, Liu, J, Abdelrahman, YM, Singh, AP, Duscha, S, Rathi, C, Lee, RB, Belland, RJ, Meibohm, B, Rosch, JW, Böttger, EC, Lee, RE. Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections. Sci Transl Med, 7 (288), 288ra75, 2015.
  28. Bruhn, DF, Scherman, MS, Liu, J, Scherbakov, D, Meibohm, B, Böttger, EC, Lenaerts, AJ, Lee, RE. In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. Sci Rep, 5, 13985, 2015.
  29. Chhim, RF, Crill, CM, Collier, HK, Arnold, SR, Pourcyrous, M, Meibohm, B, Christensen, M. Ethanol lock therapy: a pilot infusion study in infants. Ann Pharmacother, 49 (4), 431-6, 2015.
  30. Zhang, Y, Wei, X, Bajaj, G, Barrett, JS, Meibohm, B, Joshi, A, Gupta, M. Challenges and considerations for development of therapeutic proteins in pediatric patients. J Clin Pharmacol, 55 Suppl 3, S103-15, 2015.
  31. Rathi, C, Meibohm, B. Clinical pharmacology of bispecific antibody constructs. J Clin Pharmacol, 55 Suppl 3, S21-8, 2015.
  32. Rakesh, , Bruhn, DF, Scherman, MS, Woolhiser, LK, Madhura, DB, Maddox, MM, Singh, AP, Lee, RB, Hurdle, JG, McNeil, MR, Lenaerts, AJ, Meibohm, B, Lee, RE. Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. PLoS One, 9 (2), e87909, 2014.
  33. Feagan, BG, Choquette, D, Ghosh, S, Gladman, DD, Ho, V, Meibohm, B, Zou, G, Xu, Z, Shankar, G, Sealey, DC, Russell, AS. The challenge of indication extrapolation for infliximab biosimilars. Biologicals, 2014.
  34. Swaminathan, S, Li, H, Palamoor, M, de Obarrio, WT, Madhura, D, Meibohm, B, Jablonski, MM. Novel endogenous glycan therapy for retinal diseases: safety, in vitro stability, ocular pharmacokinetic modeling, and biodistribution. AAPS J, 16 (2), 311-23, 2014.
  35. Lee, RE, Hurdle, JG, Liu, J, Bruhn, DF, Matt, T, Scherman, MS, Vaddady, PK, Zheng, Z, Qi, J, Akbergenov, R, Das, S, Madhura, DB, Rathi, C, Trivedi, A, Villellas, C, Lee, RB, Rakesh, , Waidyarachchi, SL, Sun, D, McNeil, MR, Ainsa, JA, Boshoff, HI, Gonzalez-Juarrero, M, Meibohm, B, Böttger, EC, Lenaerts, AJ. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med, 20 (2), 152-8, 2014.
  36. Ramusovic, S, Läer, S, Meibohm, B, Lagler, FB, Paul, T. Pharmacokinetics of intravenous amiodarone in children. Arch Dis Child, 98 (12), 989-93, 2013.
  37. Diao, L, Meibohm, B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet, 52 (10), 855-68, 2013.
  38. Tang, W, Bentley, AR, Kritchevsky, SB, Harris, TB, Newman, AB, Bauer, DC, Meibohm, B, Cassano, PA, ,. Genetic variation in antioxidant enzymes, cigarette smoking, and longitudinal change in lung function. Free Radic Biol Med, 63, 304-12, 2013.
  39. Madhura, DB, Lee, R, Meibohm, B. Pharmacokinetic profile of spectinomycin in rats. Pharmazie, 68 (8), 675-6, 2013.
  40. Trivedi, A, Lee, RE, Meibohm, B. Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. Expert Rev Clin Pharmacol, 6 (2), 159-70, 2013.
  41. Della Casa Alberighi, O, Barrett, JS, Läer, S, Meibohm, B. Response to "Physiologically based pharmacokinetic modeling at the extremes of age". Clin Pharmacol Ther, 93 (2), 149, 2013.
  42. Bai, JP, Barrett, JS, Burckart, GJ, Meibohm, B, Sachs, HC, Yao, L. Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants. AAPS J, 2013.
  43. Thudium, K, Bilic, S, Leipold, D, Mallet, W, Kaur, S, Meibohm, B, Erickson, H, Tibbitts, J, Zhao, H, Gupta, M. American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. MAbs, 5 (1), 5-12, 2013.
  44. Rakesh, , Bruhn, D, Madhura, DB, Maddox, M, Lee, RB, Trivedi, A, Yang, L, Scherman, MS, Gilliland, JC, Gruppo, V, McNeil, MR, Lenaerts, AJ, Meibohm, B, Lee, RE. Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. Bioorg Med Chem, 20 (20), 6063-72, 2012.
  45. van den Borst, B, Gosker, HR, Koster, A, Yu, B, Kritchevsky, SB, Liu, Y, Meibohm, B, Rice, TB, Shlipak, M, Yende, S, Harris, TB, Schols, AM, ,. The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. Am J Clin Nutr, 96 (3), 516-26, 2012.
  46. Barrett, JS, Della Casa Alberighi, O, Läer, S, Meibohm, B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther, 92 (1), 40-9, 2012.
  47. Lee, DS, de Rekeneire, N, Hanlon, JT, Gill, TM, Bauer, DC, Meibohm, B, Harris, TB, Jeffery, SM. Cognitive Impairment and Medication Complexity in Community-Living Older Adults: The Health, Aging and Body Composition Study. J Pharm Technol, 28 (4), 156-162, 2012.
  48. Chirmule, N, Jawa, V, Meibohm, B. Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy. AAPS J, 14 (2), 296-302, 2012.
  49. Bentley, AR, Kritchevsky, SB, Harris, TB, Newman, AB, Bauer, DC, Meibohm, B, Clark, AG, Cassano, PA, ,. Genetic variation in antioxidant enzymes and lung function. Free Radic Biol Med, 52 (9), 1577-1583, 2012.
  50. Mehrotra, N, Tang, L, Phelps, SJ, Meibohm, B. Evaluation of vancomycin dosing regimens in preterm and term neonates using monte carlo simulations. Pharmacotherapy, 32 (5), 408-19, 2012.
  51. Kelmer, G, Bell, GC, Martin-Jimenez, T, Saxton, AM, Catasus, C, Elliot, SB, Meibohm, B. Evaluation of regional limb perfusion with amikacin using the saphenous, cephalic, and palmar digital veins in standing horses. J Vet Pharmacol Ther, 2012.
  52. Swanson, JM, Wood, GC, Xu, L, Tang, LE, Meibohm, B, Homayouni, R, Croce, MA, Fabian, TC. Developing a gene expression model for predicting ventilator-associated pneumonia in trauma patients: a pilot study. PLoS One, 7 (8), e42065, 2012.
  53. Aldrich, MC, Kumar, R, Colangelo, LA, Williams, LK, Sen, S, Kritchevsky, SB, Meibohm, B, Galanter, J, Hu, D, Gignoux, CR, Liu, Y, Harris, TB, Ziv, E, Zmuda, J, Garcia, M, Leak, TS, Foreman, MG, Smith, LJ, Fornage, M, Liu, K, Burchard, EG, ,. Genetic ancestry-smoking interactions and lung function in African Americans: a cohort study. PLoS One, 7 (6), e39541, 2012.
  54. Meibohm, B, Zhou, H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol, 52 (1 Suppl), 54S-62S, 2012.
  55. Budha, NR, Kovar, A, Meibohm, B. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. AAPS J, 13 (4), 650-61, 2011.
  56. Meibohm, B. Population pharmacokinetic/pharmacodynamic analyses as the basis for dosing of therapeutic monoclonal antibodies. Clin Pharmacokinet, 50 (12), 823-4, 2011.
  57. van den Borst, B, Koster, A, Yu, B, Gosker, HR, Meibohm, B, Bauer, DC, Kritchevsky, SB, Liu, Y, Newman, AB, Harris, TB, Schols, AM. Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking. Thorax, 66 (11), 961-9, 2011.
  58. Prado, ME, Ryman, JT, Boileau, MJ, Martin-Jimenez, T, Meibohm, B. Pharmacokinetics of ponazuril after oral administration to healthy llamas (Lama glama). Am J Vet Res, 72 (10), 1386-9, 2011.
  59. Läer, S, Meibohm, B. Study design and simulation approach. Handb Exp Pharmacol, 205, 125-48, 2011.
  60. Bai, JP, Bell, R, Buckman, S, Burckart, GJ, Eichler, HG, Fang, KC, Goodsaid, FM, Jusko, WJ, Lesko, LL, Meibohm, B, Patterson, SD, Puig, O, Smerage, JB, Snider, BJ, Wagner, JA, Wang, J, Walton, MK, Weiner, R. Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J, 13 (2), 274-83, 2011.
  61. Vaddady, PK, Mehrotra, N, Zhang, X, Yates, CR, Moore, BM, Meibohm, B. Pharmacokinetics of a combination of Δ9-tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock. Biopharm Drug Dispos, 32 (2), 89-98, 2011.
  62. Chen, J, Wang, Z, Li, CM, Lu, Y, Vaddady, PK, Meibohm, B, Dalton, JT, Miller, DD, Li, W. Discovery of Novel 2-Aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem, 53 (20), 7414-27, 2010.
  63. Dirks, NL, Meibohm, B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet, 49 (10), 633-59, 2010.
  64. Romero, K, Corrigan, B, Tornoe, CW, Gobburu, JV, Danhof, M, Gillespie, WR, Gastonguay, MR, Meibohm, B, Derendorf, H. Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol, 50 (9 Suppl), 9S-19S, 2010.
  65. Vaddady, PK, Lee, RE, Meibohm, B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med Chem, 2 (8), 1355-69, 2010.
  66. Kumar, R, Seibold, MA, Aldrich, MC, Williams, LK, Reiner, AP, Colangelo, L, Galanter, J, Gignoux, C, Hu, D, Sen, S, Choudhry, S, Peterson, EL, Rodriguez-Santana, J, Rodriguez-Cintron, W, Nalls, MA, Leak, TS, O'Meara, E, Meibohm, B, Kritchevsky, SB, Li, R, Harris, TB, Nickerson, DA, Fornage, M, Enright, P, Ziv, E, Smith, LJ, Liu, K, Burchard, EG. Genetic ancestry in lung-function predictions. N Engl J Med, 363 (4), 321-30, 2010.
  67. Mehrotra, N, Freire, AX, Bauer, DC, Harris, TB, Newman, AB, Kritchevsky, SB, Meibohm, B, ,. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol, 20 (3), 223-32, 2010.
  68. Sharma, A, Pibarot, P, Pilote, S, Dumesnil, JG, Arsenault, M, Bélanger, PM, Meibohm, B, Hamelin, BA. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction. J Clin Pharmacol, 50 (2), 214-25, 2010.
  69. Budha, NR, Lee, RB, Hurdle, JG, Lee, RE, Meibohm, B. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinb), 2009.
  70. Läer, S, Barrett, JS, Meibohm, B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol, 49 (8), 889-904, 2009.
  71. Dirks, NL, Li, S, Huth, B, Hochhaus, G, Yates, CR, Meibohm, B. Transrepression and transactivation potencies of inhaled glucocorticoids. Pharmazie, 63 (12), 893-8, 2008.
  72. Zhang, Y, Mehrotra, N, Budha, NR, Christensen, ML, Meibohm, B. A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens. Clin Chim Acta, 398 (1-2), 105-12, 2008.
  73. Zhang, L, Pfister, M, Meibohm, B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J, 10 (4), 552-9, 2008.
  74. Hurdle, JG, Lee, RB, Budha, NR, Carson, EI, Qi, J, Scherman, MS, Cho, SH, McNeil, MR, Lenaerts, AJ, Franzblau, SG, Meibohm, B, Lee, RE. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother, 62 (5), 1037-45, 2008.
  75. Mertens-Talcott, SU, Rios, J, Jilma-Stohlawetz, P, Pacheco-Palencia, LA, Meibohm, B, Talcott, ST, Derendorf, H. Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers. J Agric Food Chem, 56 (17), 7796-802, 2008.
  76. Albers, S, Meibohm, B, Mir, TS, Läer, S. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol, 65 (4), 511-22, 2008.
  77. Budha, NR, Lee, RE, Meibohm, B. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Curr Med Chem, 15 (8), 809-25, 2008.
  78. Dirks, NL, Nolting, A, Kovar, A, Meibohm, B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol, 48 (3), 267-78, 2008.
  79. Budha, NR, Mehrotra, N, Tangallapally, R, Rakesh, , Qi, J, Daniels, AJ, Lee, RE, Meibohm, B. Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. AAPS J, 10 (1), 157-65, 2007.
  80. Tangallapally, RP, Sun, D, Rakesh, , Budha, N, Lee, RE, Lenaerts, AJ, Meibohm, B, Lee, RE. Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorg Med Chem Lett, 17 (23), 6638-42, 2007.
  81. Chen, ML, Straughn, AB, Sadrieh, N, Meyer, M, Faustino, PJ, Ciavarella, AB, Meibohm, B, Yates, CR, Hussain, AS. A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharm Res, 24 (1), 73-80, 2007.
  82. Mehrotra, N, Gupta, M, Kovar, A, Meibohm, B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res, 19 (3), 253-64, 2006.
  83. Song, P, Lamba, JK, Zhang, L, Schuetz, E, Shukla, N, Meibohm, B, Yates, CR. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol, 46 (3), 373-9, 2006.
  84. Meibohm, B, Läer, S, Panetta, JC, Barrett, JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J, 7 (2), E475-87, 2005.
  85. Läer, S, Elshoff, JP, Meibohm, B, Weil, J, Mir, TS, Zhang, W, Hulpke-Wette, M. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol, 46 (7), 1322-30, 2005.
  86. Christensen, ML, Meibohm, B, Capparelli, EV, Velasquez-Mieyer, P, Burghen, GA, Tamborlane, WV. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol, 45 (10), 1137-44, 2005.
  87. Gupta, M, Yates, CR, Meibohm, B. SYBR Green-based real-time PCR allelic discrimination assay for beta2-adrenergic receptor polymorphisms. Anal Biochem, 344 (2), 292-4, 2005.
  88. Gupta, M, Kovar, A, Meibohm, B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol, 45 (9), 987-1003, 2005.
  89. Song, P, Meibohm, B, Yates, CR. LC/MS/MS in drug development: targeting the brain. Biotechniques, Suppl, 19-23, 2005.
  90. Sharma, A, Pibarot, P, Pilote, S, Dumesnil, JG, Arsenault, M, Bélanger, PM, Meibohm, B, Hamelin, BA. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther, 313 (3), 1172-81, 2005.
  91. Dirks, NL, Huth, B, Yates, CR, Meibohm, B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther, 42 (12), 701-18, 2004.
  92. Tang, L, Persky, AM, Hochhaus, G, Meibohm, B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci, 93 (9), 2184-204, 2004.
  93. Gupta, M, Song, P, Yates, CR, Meibohm, B. Real-time PCR-based genotyping assay for CXCR2 polymorphisms. Clin Chim Acta, 341 (1-2), 93-100, 2004.
  94. Yates, CR, Zhang, W, Song, P, Li, S, Gaber, AO, Kotb, M, Honaker, MR, Alloway, RR, Meibohm, B. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol, 43 (6), 555-64, 2003.
  95. Song, P, Li, S, Meibohm, B, Gaber, AO, Honaker, MR, Kotb, M, Yates, CR. Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci, 4 (4), E29, 2003.
  96. Läer, S, Mir, TS, Behn, F, Eiselt, M, Scholz, H, Venzke, A, Meibohm, B, Weil, J. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J, 143 (5), 916-22, 2002.
  97. Meibohm, B, Beierle, I, Derendorf, H. How important are gender differences in pharmacokinetics. Clin Pharmacokinet, 41 (5), 329-42, 2002.
  98. Meibohm, B, Derendorf, H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci, 91 (1), 18-31, 2002.
  99. Läer, S, Meibohm, B, Mir, TS, Hulpke-Wette, M. Termination of automatic atrial tachycardia in an infant by adequate sotalol dosing. Indication of clinically relevant age-dependent pharmacokinetics of sotalol. Eur J Clin Pharmacol, 57 (2), 181-2, 2001.
  100. Meibohm, B, Zhang, W, Beierle, I, Meyer, MC. Epistaxis associated with elevation of INR in a patient switched to generic warfarin--another view. Pharmacotherapy, 20 (7), 866-9; discussion 869-71, 2000.
  101. Derendorf, H, Hochhaus, G, Krishnaswami, S, Meibohm, B, Möllmann, H. Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism. Pharmazie, 55 (3), 223-7, 2000.
  102. Beierle, I, Meibohm, B, Derendorf, H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther, 37 (11), 529-47, 1999.
  103. Meibohm, B, Derendorf, H, Möllmann, H, Fröhlich, P, Tromm, A, Wagner, M, Homrighausen, S, Krieg, M, Hochhaus, G. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther, 37 (8), 367-76, 1999.
  104. Meibohm, B, Hochhaus, G, Möllmann, H, Barth, J, Wagner, M, Krieg, M, Stöckmann, R, Derendorf, H. A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm, 27 (2), 127-47, 1999.
  105. Derendorf, H, Meibohm, B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res, 16 (2), 176-85, 1999.
  106. Derendorf, H, Hochhaus, G, Meibohm, B, Möllmann, H, Barth, J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol, 101 (4 Pt 2), S440-6, 1998.
  107. Möllmann, H, Wagner, M, Meibohm, B, Hochhaus, G, Barth, J, Stöckmann, R, Krieg, M, Weisser, H, Falcoz, C, Derendorf, H. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol, 53 (6), 459-67, 1998.
  108. Meibohm, B, Derendorf, H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther, 35 (10), 401-13, 1997.
  109. Derendorf, H, Möllmann, H, Hochhaus, G, Meibohm, B, Barth, J. Clinical PK/PD modelling as a tool in drug development of corticosteroids. Int J Clin Pharmacol Ther, 35 (10), 481-8, 1997.
  110. Möllmann, H, Derendorf, H, Barth, J, Meibohm, B, Wagner, M, Krieg, M, Weisser, H, Knöller, J, Möllmann, A, Hochhaus, G. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol, 37 (10), 893-903, 1997.
  111. Meibohm, B, Hochhaus, G, Rohatagi, S, Möllmann, H, Barth, J, Wagner, M, Krieg, M, Stöckmann, R, Derendorf, H. Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol, 37 (8), 704-10, 1997.
  112. Rohatagi, S, Bye, A, Falcoz, C, Mackie, AE, Meibohm, B, Möllmann, H, Derendorf, H. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol, 36 (10), 938-41, 1996.